WHA78 individual statement on antimicrobial resistance (AMR)
On 27 May 2025, IFPMA delievered a statement at the 78th session of the World Health Assembly on antimicrobial resistance.
We welcome the concrete commitments made by UN Member States in the 2024 UN High Level Meeting (HLM) Political Declaration on AMR and the multistakeholder engagement in the process. Among others, the industry reported important R&D progress through the AMR Action Fund, contributed important research on the actions needed to further revitalize the antibiotic innovation ecosystem, outlined pathways for access to existing and new antibiotics, and showcased the worrying exodus of AMR research expertise. We stand ready to engage in the follow-up processes tied to the HLM outcomes.
We have previously expressed our general support for WHO 2025-2035 priorities on AMR and reiterate the urgent need to progress effective R&D incentive mechanisms and sustainable access mechanisms to tackle the pipeline and access crisis, ahead of the planned 2029 UN AMR HLM.
Finally, we support the efforts to undertake the revision of the Global Action Plan on AMR, leveraging the collective advances in understanding the AMR burden and the solutions needed to tackle it, and look forward to providing our expertise in the process.
About IFPMA
IFPMA represents the innovative pharmaceutical industry at the international level, engaging in official relations with the United Nations and multilateral organizations. Our vision is to ensure that scientific progress translates into the next generation of medicines and vaccines that deliver a healthier future for people everywhere.
ifpma.org
To achieve this, we act as a trusted partner, bringing our members' expertise to champion pharmaceutical innovation, drive policy that supports the research, development, and delivery of health technologies, and create sustainable solutions that advance global health.
Related news and resources
158th session of the WHO Executive Board (EB158): Draft updated global action plan on antimicrobial resistance
On 4 February 2026, IFPMA delivered a statement on Agenda item 14 on the draft updated global action plan on antimicrobial resistance (AMR) at the 158th session of the WHO Executive Board. We welcome the timely update of the Global Action Plan on AMR (GAP), which provides a unique opportunity to take stock of progress...
Read moreRevitalizing the antibiotic pipeline by implementing new R&D pull incentives
With the 2024 UN High-Level Meeting on antimicrobial resistance (AMR) and its political declaration, together with the biennial AMR Ministerial Meeting, the world has set an ambitious agenda to tackle AMR. The next four years offer renewed political momentum to deliver progress ahead of the next UN High-Level Meeting on AMR in 2029. A central priority is creating the necessary policy frameworks that stimulate R&D investment. This brief identifies the key barriers to antibiotic R&D and the policy measures needed to address them. Sustainable, effective pull incentives are urgently required to ensure a reliable pipeline of new antibiotics for patients and health systems. We set out how these incentives should be designed and implemented, guided by a set of core principles to maximize their impact.
Read more
Open letter from the innovative pharmaceutical industry to G7 leaders
Ahead of the G7 Leaders’ Summit in Kananaskis from 15 to 17 2025, the global pharmaceutical industry, represented by the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) and Innovative Medicines Canada (IMC), are calling on G7 governments to place health and innovation at the top of their agenda.
Read more